<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04969627</url>
  </required_header>
  <id_info>
    <org_study_id>2020PS624K</org_study_id>
    <nct_id>NCT04969627</nct_id>
  </id_info>
  <brief_title>Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.</brief_title>
  <official_title>Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bing He</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shengjing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of GLP-1 analogues combined with metformin and metformin on gonadal and&#xD;
      metabolic profiles in PCOS patients with BMI ≥ 24 in China. 60 cases of overweight PCOS&#xD;
      patients were collected from Shengjing hospital. The intervention period was 3 months after&#xD;
      intervention with met or met + GLP-1. To evaluate the improvement of met or met + GLP-1 in&#xD;
      the treatment of hyperandremia, glucose metabolism, BMI, waist circumference, menstruation,&#xD;
      hairiness and acne in PCOS patients with different BMI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in body weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in body mass index (BMI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in body mass index (BMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference(WC)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in waist circumference(WC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ferriman-Gallwey score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in Ferriman-Gallwey score，the range of Ferriman-Gallwey score is 0-9, higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Acne severity score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in Acne severity score,the range of acne severity score is 0-9, higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in frequency of menstrual cycle</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in frequency of menstrual cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Blood Glucose and Insulin During the oral glucose tolerance test (OGTT)</measure>
    <time_frame>12 weeks</time_frame>
    <description>glucose obtained at 0,30,60 and 120 minutes during the OGTT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Luteinizing Hormone (LH)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in Luteinizing Hormone (LH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in follicle stimulating hormone (FSH)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in follicle stimulating hormone (FSH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LH/FSH</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in LH/FSH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in prolactin (PRL)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in prolactin (PRL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in progesterone (Prog)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in progesterone (Prog)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total testosterone (TT)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in total testosterone (TT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in free testosterone (FT)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in free testosterone (FT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in free androgen index (FAI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in free androgen index (FAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sex hormone binding globulin (SHBG)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in sex hormone binding globulin (SHBG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in dehydroepiandrosterone sulfate (DHEAS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in dehydroepiandrosterone sulfate (DHEAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in anti-müllerian hormone (AMH)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in anti-müllerian hormone (AMH)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Metformin (BMI&lt;24)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects: PCOS patients whoseBMI&lt;24 Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin (BMI≥24)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects: PCOS patients whoseBMI≥24 Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination (BMI&lt;24)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects: PCOS patients whoseBMI&lt;24 Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination (BMI≥24)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects: PCOS patients whoseBMI≥24 Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Use Metformin for 3 months to treat PCOS</description>
    <arm_group_label>Combination (BMI&lt;24)</arm_group_label>
    <arm_group_label>Combination (BMI≥24)</arm_group_label>
    <arm_group_label>Metformin (BMI&lt;24)</arm_group_label>
    <arm_group_label>Metformin (BMI≥24)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Use Exenatide for 3 months to treat PCOS</description>
    <arm_group_label>Combination (BMI&lt;24)</arm_group_label>
    <arm_group_label>Combination (BMI≥24)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females 18 years to 40 years of age Diagnosed as PCOS by the 2003 Rotterdam criteria&#xD;
&#xD;
          2. Overweight/obesity (BMI≥24 kg/m2)&#xD;
&#xD;
          3. No pregnant plan in recent 6 months&#xD;
&#xD;
          4. Written consent for participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. type 1 or type 2 diabetes mellitus&#xD;
&#xD;
          2. Subjects have other endocrine diseases, such as adrenal hyperplasias or tumor,&#xD;
             androgen-secreting tumors, Cushing's syndrome, thyroid diseases, and&#xD;
             hyperprolactinemia&#xD;
&#xD;
          3. Diagnosed with or have a family history of medullary thyroid carcinoma (MTC) or&#xD;
             Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)&#xD;
&#xD;
          4. Serious systemic disease or malignant tumor&#xD;
&#xD;
          5. History of pancreatitis (chronic, acute or recurrent)&#xD;
&#xD;
          6. Body weight change ≥10% at 3 months before treatment&#xD;
&#xD;
          7. Used oral contraceptives or sex hormone drugs in the past 1 month&#xD;
&#xD;
          8. Used oral glucocorticoids in the past 1 month&#xD;
&#xD;
          9. Substance (alcohol or drug) abuse or dependence within 3 months&#xD;
&#xD;
         10. Heavy smokers (smokers who smoke 20 or more cigarettes a day) or heavy drinkers&#xD;
             (&gt;10g/d)&#xD;
&#xD;
         11. Subjects have a severe systemic disease, such as cardiovascular system, Renal&#xD;
             impairment (eGFR&lt;60ml/min/1.73m2)&#xD;
&#xD;
         12. Increase of transaminases up to &lt; 2.5 times of upper limit of normal value&#xD;
&#xD;
         13. Have a history of thromboembolic disease or thrombotic tendency&#xD;
&#xD;
         14. Subjects in pregnant or lactating or within 1 year after delivery&#xD;
&#xD;
         15. Subjects have an allergic history to the drugs used in the study&#xD;
&#xD;
         16. Subjects have participated in other clinical researches of medicine within 1 month&#xD;
             prior to randomization&#xD;
&#xD;
         17. Use of metformin, glucagon-like peptide -1 receptor agonists, or weight loss&#xD;
             medications (prescription or OTC) within 30 days before screening&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bing He, Dr</last_name>
    <phone>18940259707</phone>
    <email>hebing7557@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bing He, Dr</last_name>
      <phone>18940259707</phone>
      <email>hebing7557@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 17, 2021</last_update_submitted>
  <last_update_submitted_qc>July 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shengjing Hospital</investigator_affiliation>
    <investigator_full_name>Bing He</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

